Citigroup Inc Bio N Tech Se Call Options Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$78.36 - $124.66 $125,376 - $199,456	-1,600 Reduced 6.43%	23,300 $2.77 Million
Q2 2024 Aug 12, 2024	BUY	$80.36 - $102.87 $2 Million - $2.56 Million	24,900 New	24,900 $2 Million
Q4 2023 Feb 09, 2024	BUY	$90.91 - $112.75 $1.84 Million - $2.28 Million	20,200 Added 118.82%	37,200 $3.93 Million
Q2 2023 Aug 10, 2023	BUY	$102.58 - $129.66 $512,900 - $648,300	5,000 Added 41.67%	17,000 $1.83 Million
Q1 2023 May 11, 2023	SELL	$122.57 - $153.67 $18.2 Million - $22.8 Million	-148,500 Reduced 92.52%	12,000 $1.49 Million
Q3 2022 Nov 10, 2022	SELL	$127.65 - $183.11 $8.9 Million - $12.8 Million	-69,700 Reduced 30.28%	160,500 $21.6 Million
Q2 2022 Aug 10, 2022	SELL	$123.25 - $186.24 $20.5 Million - $30.9 Million	-166,000 Reduced 41.9%	230,200 $34.3 Million
Q1 2022 May 12, 2022	SELL	$126.25 - $231.85 $4.89 Million - $8.97 Million	-38,700 Reduced 8.9%	396,200 $67.6 Million
Q4 2021 Feb 10, 2022	BUY	$216.64 - $362.52 $27.8 Million - $46.6 Million	128,500 Added 41.94%	434,900 $112 Million
Q3 2021 Nov 10, 2021	BUY	$205.93 - $447.23 $63.1 Million - $137 Million	306,400 New	306,400 $83.6 Million

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.